15 results about "Plasmapheresis" patented technology

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

Provided herein are methods of removing microplastics from the blood or the body of a subject, including one or more tissues of the subject, by extracorporeal blood purification (EBP), including by plasmapheresis, such as double-filtration plasmapheresis (DFPP). In other aspects are provided methods of treating medical conditions and methods of improving healthspan and lifespan using extracorporeal blood purification, including plasmapheresis, such as DFPP, for example by filtering microplastics from the blood, and otherwise removing microplastics from the tissues or body of a subject, such as a human subject.

The present disclosure provides methods and systems for removing particles from an individual using plasmapheresis, including from an individual's circulatory system, blood vessels, and / or organs. In various embodiments, the particles removed are plastic particles. In further embodiments, the present disclosure provides methods for treatment by reducing levels of particles in an individual's circulatory system, blood vessels, and / or organs.

Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

The invention relates to a hollow fiber membrane for separating blood plasma from blood, comprising a blood contact layer and a support layer, each having a hydrophobic polymer, a hydrophilic polymer and vitamin E, and to a method for producing this hollow fiber membrane for providing a hollow fiber membrane. The hollow fiber membrane is characterized by a reduced hemolysis activity, so that the hollow fiber membrane can be advantageously used in plasmapheresis methods.

Provided herein are methods of removing PFAS from the blood or the body of a subject, including one or more tissues of the subject, by extracorporeal blood purification (EBP), including by plasmapheresis, such as double-filtration plasmapheresis (DFPP). In other aspects are provided methods of treating medical conditions and methods of improving healthspan and lifespan using extracorporeal blood purification, including plasmapheresis, such as DFPP, for example by filtering PFAS from the blood, and otherwise removing PFAS from the tissues or body of a subject, such as a human subject.

A plasmapheresis centrifuge bowl includes an outer body that is rotatable about a longitudinal axis of the plasmapheresis centrifuge bowl. The outer body has a main body defining an interior, a neck portion extending proximal to the main body, and a shoulder connecting the main body and the neck portion. Within the interior, the bowl has a separation region, and rotation of the bowl separates whole blood within the separation region into a first blood component and a second blood component. The bowl also includes an actuating seal mechanism that transitions between an open state when the plasmapheresis centrifuge bowl is rotating and a closed state when the plasmapheresis centrifuge bowl is not rotating.

A hollow fiber membrane for separating blood plasma from blood, comprising a blood contact layer and a support layer each comprising a hydrophobic polymer, a hydrophilic polymer and vitamin E, and a method for producing said hollow fiber membrane to provide a hollow fiber membrane is described. The hollow fiber membrane is characterized by a reduced hemolysis activity so that the hollow fiber membrane can be advantageously used in plasmapheresis methods.

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

The present application belongs to the technical field of plasma separator, and particularly relates to a centrifugal glue filling process of a plasma separator. The process comprises the following steps: installing a sintered membrane into a shell of the plasma separator and sealing two ends of the membrane with glue injection covers to obtain a glue filling assembly; installing the glue filling assembly into a centrifugal bucket and setting a temperature of the centrifugal bucket; mixing A and B glues through a glue injector to obtain glue, and filling the glue into a glue distributor; setting a residence time of the glue in the glue distributor, a centrifugal rotating speed and a temperature of the centrifugal bucket, and distributing the glue in the glue distributor to two ends of the glue distributor under the action of centrifugal force; closing the centrifugal force after the glue is solidified under solidification conditions, taking out the plasma separator, and completing the glue filling; and controlling the residence time of the mixed A and B glues in the glue distributor to make the glue partially react and increase the viscosity, so that the glue is not easy to enter into the hollow fiber membrane of the plasma separator, and the problems of product hole blocking and hollow fiber membrane hole blocking caused by the centrifugal glue filling of the plasma separator are solved.

The embodiment of the application belongs to the technical field of medical apparatuses, and particularly relates to a plasma separation machine. The embodiment of the application aims to solve the problem that the plasma separated by the related plasma separation machine is prone to denaturation. The plasma separation machine comprises a box body, a centrifugal machine, a plasma output assembly and a cooling device, the centrifugal machine, the plasma output assembly and the cooling device are all arranged in the box body, the plasma output assembly comprises a plasma tube and a plasma bag, the centrifugal machine has a liquid inlet end and a liquid outlet end, the liquid inlet end is configured to receive blood from a human body, the liquid outlet end is communicated with the plasma bag through the plasma tube, and the cooling device is configured to cool the plasma in at least one of the plasma bag and the plasma tube. Through the above arrangement, the cooling device cools the plasma in the plasma bag and / or the plasma tube, so as to reduce the temperature of the plasma in the plasma tube and the plasma bag, thereby preventing the plasma protein from denaturation and the coagulation factor from losing activity, and improving the quality of the plasma in the plasma bag.

A hollow fiber membrane comprising polyethersulfone, wherein the hollow fiber membrane has a structure that is non-uniform in a thickness direction, and a gradient index which is a ratio of an average pore size at an inner surface side in a cross section of the hollow fiber membrane to an average pore size at an outer surface side in the cross section is 2.00 or more.

The present disclosure provides methods and systems for removing particles from an individual using plasmapheresis, including from an individual's circulatory system, blood vessels, and / or organs. In various embodiments, the particles removed are plastic particles. In further embodiments, the present disclosure provides methods for treatment by reducing levels of particles in an individual's circulatory system, blood vessels, and / or organs.